Press release -
Chr. Hansen will showcase research on its newest Swine probiotic at the Congress on Gastrointestinal Function in Chicago
Research confirming the effective in vitro inhibition of the growth of E. coli will be showcased at the Congress on Gastrointestinal Function, where other central studies with livestock and poultry species for food production and biomedical research, as well as clinical and nutritional studies relevant to improving human health and well-being will be presented.
Chr. Hansen’s latest innovation in Swine Probiotics – PorcBoost® EB - has proven to be effective in vitro at inhibiting the growth of pathogenic E. coli and at the same time preventing the adherence of pathogenic E. coli to the epithelia of the intestinal wall. Likewise, when consumed, the highly-selected Bacillus strain contained in PorcBoost® EB leads to a demonstrable benefit in the performance of pigs. Piglets with reduced burdens of pathogenic E. coli are likely to have reduced frequency and severity of E. coli-induced scours, and will perform better.
This research will be showcased at the Congress on Gastrointestinal Function in Chicago – a place where academic and industry scientists gather to present the latest advances in understanding of gastrointestinal microbiology, physiology and nutritional sciences.
Inhibiting E. coli in piglets
E. coli infections give rise to high mortality rates and poor production performance in piglets. PorcBoost® EB contains a naturally-occurring, unique bacterial strain of Bacillus subtilis carefully selected for its E. coli inhibitory and competitive features. It is provided in feed in the form of spores, which are a dormant stage that can transform to a vegetative cell in the digestive tract of the pig. PorcBoost® EB – has proven to enhance daily weight gain and feed conversion, as well as improve fecal scoring.
The research on PorcBoost® EB will be showcased during a podium presentation at the 2017 CGIF in Chicago, USA. The congress showcases the latest in understanding of the gut microbiome as it interacts with the nutrition, ecology, and health of livestock species as well as humans and pets.
“The congress is a place where the latest in understanding of the gut microbiome is showcased. With microbial solutions at the very heart of Chr. Hansen’s business, it is only natural that we will be there to share our latest innovations, research and insights – in particular within the Swine category,” says Vilson Simon, Senior Vice President for Animal Health at Chr. Hansen.
Ramona Cernat and Bea Nielsen are the specialists in Swine health at Chr. Hansen who led the research projects for PorcBoost® EB:
“Research results have demonstrated that feed supplementation of newly weaned piglets with PorcBoost® EB had a numeric or significant effect on daily gain and feed conversion, as well as improved fecal scoring. The outcomes suggest that PorcBoost® EB’s protective effect is more likely to be pathogen-specific. We look forward to sharing more of the data and findings at the Congress in Chicago.”
Information about Chr. Hansen’s expanded range of microbial products and services for Animal Health will also be available at the Congress.
Science-based, Research-proven
At Chr. Hansen, ‘good-bacteria’ is at the heart of our business model, and we are first movers in innovation and technology when it comes to understanding the complexities of the probiotic modes of action and the gut microbiome – in humans and in animals. As such, our product innovations stem from our strong platforms in bioscience technologies and an in-depth understanding of the needs in the market. That is why we call our approach Science-based, Research-proven.
In the case of PorcBoost® EB, this included in vitro screening for antibiotic susceptibility, lack of virulence genes, tolerance to bile and acid pH, sporulation and antimicrobial activity against ETEC O149:K91:F4ac and O147:K89:F4, E.coli O101:K-:F5, Cl. perfringens Type A and Type C and S. typhimurium strains. The adhesion of Bacillus sp. spores and vegetative cells to Caco-2, mucus-secreting HT-29 MTX and porcine jejunal IPEC-J2 cells was also investigated. The pathogenic E. coli strains were further used as in vitro challenged models. The top lead candidates were selected for in vivo trials.
2017 Congress on Gastrointestinal Function
You can meet representatives from Chr. Hansen to learn more about PorcBoost EB, our research and all our probiotic solutions for Animal Health during the 3-day Congress on Gastrointestinal Function in Chicago from 10-12 April. You can also see Ramona Cernat, a Senior Research Scientist and specialist in Swine health at Chr. Hansen, hold a podium presentation on PorcBoost® EB on Wednesday, April 12 from at 9am:
- PorcBoost® EB: a new Bacillus subtilis-based probiotic that improves gut health in piglets R. Cernat, B. Nielsen; Chr. Hansen A/S, Hørsholm, Denmark
Topics
Categories
Chr. Hansen is a leading, global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. We develop and produce cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements and even animal feed and plant protection. Our product innovation is based on more than 30,000 microbial strains – we like to refer to them as ‘good bacteria’. Our solutions enable food manufacturers to produce more with less – while also reducing the use of chemicals and other synthetic additives – which make our products highly relevant in today’s world. We have been delivering value to our partners – and, ultimately, end consumers worldwide – for over 140 years. We are proud that more than one billion people consume products containing our natural ingredients every day. Revenue in the 2016/17 financial year was EUR 1,063 million. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen.
